BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38810948)

  • 1. Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases.
    Salem S; Kilgore MD; Anwer M; Maxan A; Child D; Bird TD; Keene CD; Cicchetti F; Latimer C
    Neurobiol Dis; 2024 Aug; 198():106542. PubMed ID: 38810948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease.
    Cisbani G; Maxan A; Kordower JH; Planel E; Freeman TB; Cicchetti F
    Brain; 2017 Nov; 140(11):2982-2992. PubMed ID: 29069396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant huntingtin is present in neuronal grafts in Huntington disease patients.
    Cicchetti F; Lacroix S; Cisbani G; Vallières N; Saint-Pierre M; St-Amour I; Tolouei R; Skepper JN; Hauser RA; Mantovani D; Barker RA; Freeman TB
    Ann Neurol; 2014 Jul; 76(1):31-42. PubMed ID: 24798518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
    Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
    Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tau in the pathological process and clinical expression of Huntington's disease.
    Vuono R; Winder-Rhodes S; de Silva R; Cisbani G; Drouin-Ouellet J; ; Spillantini MG; Cicchetti F; Barker RA
    Brain; 2015 Jul; 138(Pt 7):1907-18. PubMed ID: 25953777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
    Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
    Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
    Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
    Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
    Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
    Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease.
    Ast A; Buntru A; Schindler F; Hasenkopf R; Schulz A; Brusendorf L; Klockmeier K; Grelle G; McMahon B; Niederlechner H; Jansen I; Diez L; Edel J; Boeddrich A; Franklin SA; Baldo B; Schnoegl S; Kunz S; Purfürst B; Gaertner A; Kampinga HH; Morton AJ; Petersén Å; Kirstein J; Bates GP; Wanker EE
    Mol Cell; 2018 Sep; 71(5):675-688.e6. PubMed ID: 30193095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bim contributes to the progression of Huntington's disease-associated phenotypes.
    Roberts SL; Evans T; Yang Y; Fu Y; Button RW; Sipthorpe RJ; Cowan K; Valionyte E; Anichtchik O; Li H; Lu B; Luo S
    Hum Mol Genet; 2020 Jan; 29(2):216-227. PubMed ID: 31813995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human-to-mouse prion-like propagation of mutant huntingtin protein.
    Jeon I; Cicchetti F; Cisbani G; Lee S; Li E; Bae J; Lee N; Li L; Im W; Kim M; Kim HS; Oh SH; Kim TA; Ko JJ; Aubé B; Oueslati A; Kim YJ; Song J
    Acta Neuropathol; 2016 Oct; 132(4):577-92. PubMed ID: 27221146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
    Lu B; Palacino J
    FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2017 Sep; 37(39):9550-9563. PubMed ID: 28893927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.
    St-Amour I; Turgeon A; Goupil C; Planel E; Hébert SS
    Acta Neuropathol; 2018 Feb; 135(2):249-265. PubMed ID: 29134321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development.
    Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
    PLoS One; 2016; 11(5):e0155834. PubMed ID: 27196694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.
    Zhao T; Hong Y; Li S; Li XJ
    J Neurosci; 2016 Aug; 36(32):8317-28. PubMed ID: 27511006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic effects of mutant huntingtin in axons are mediated by its proline-rich domain.
    Brady ST; Mesnard-Hoaglin NA; Mays S; Priego M; Dziechciowska J; Morris S; Kang M; Tsai MY; Purks JL; Klein A; Gaona A; Melloni A; Connors T; Hyman B; Song Y; Morfini GA
    Brain; 2024 Jun; 147(6):2098-2113. PubMed ID: 37633260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.